WEEKLY e-ALERT [ BASIC EDITION ]
Pharma China (www.pharmachinaonline.com) is the most influential English media and source of business intelligence covering the Chinese pharmaceutical sector. Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China’s burgeoning but increasingly complex healthcare marketplace, and is subscribed by most MNC pharma companies, leading CROs, investment banks, consulting firms active in China as well as relevant industry associations and government agencies.

Note: To view full text of free articles, you need to register as a basic member first and then log in. To view premium articles, you need to subscribe to Pharma China as a premium member. For more information or subscription, please contact info@pharmachinaonline.com. If you wish to unsubscribe from this e-Alert, please reply this e-mail with "Remove" in the subject line.
  • Industry News
  • Vivatides Emerges With $10M Seed Round to Advance Extrahepatic RNAi Platform(4/13/2026) (Premium)
  • GenScript Partners With Mimulus to Industrialize DNA Data Storage for the AI Era(4/13/2026) (Premium)
  • Haisco Signs Global ex-China Pain Deal With AbbVie for Selective Nav1.8 Inhibitors(4/13/2026) (Premium)
  • China-Indonesia Deepens HPV Vaccine Collaboration to Expand Access and Local Manufacturing(4/14/2026) (Premium)
  • Immorna Reports FIC Clinical Signal for In Vivo CAR-T in Systemic Sclerosis(4/15/2026) (Premium)
  • DualityBio Advances Shanghai STAR Market Listing Plan With Proposed CNY Share Offering(4/15/2026) (Premium)
  • CStone Launches Discounted Share Placement to Raise About HK$1.05B(4/15/2026) (Premium)
  • AB-Raybio Raises ~CNY 100M to Advance Next-Gen RDC Pipeline(4/16/2026) (Premium)
  • Kailera Targets Up to US$528.5M Nasdaq IPO to Advance Four China-Sourced Obesity Programs(4/16/2026) (Premium)
  • Biogen Maps Long-Term China Partnership Strategy as Cross-Border Innovation Accelerates(4/16/2026) (Premium)
  • Mochida Partners with Qilu Pharma to Bring Follitropin Alfa Biosimilar to Japan(4/16/2026) (Premium)
  • Luofang Bio Raises Seed Funding to Advance Polymer Thera Platform(4/16/2026) (Premium)
  • Boehringer Ingelheim and Zai Lab Partner on Dual DLL3 Strategy in Neuroendocrine Cancers(4/16/2026) (Premium)
  • Evive Expands European Footprint as Ryzneuta Deal Covers Italy and Poland(4/16/2026) (Premium)
  • Adlai Nortye Secures US$150M Oversubscribed PIPE to Advance RAS-Targeting Pipeline(4/16/2026) (Premium)
  • Aligos Signs Up to US$445M China HBV Deal With Amoytop for Capsid Assembly Modulator(4/16/2026) (Premium)
  • China Poised to Trigger Global Price War in Weight-Loss Drugs as GLP-1 Competition Intensifies(4/16/2026) (Premium)
  • Product/R&D News
  • BeOne Secures China Conditional Approval for Imdylltra in Third-Line Extensive-Stage Small Cell Lung Cancer(4/13/2026) (Premium)
  • AstraZeneca's Imjudo Wins China Approval, Likely for First-Line EGFR/ALK-Wild-Type Metastatic NSCLC Combination Use(4/13/2026) (Premium)
  • CanSino Wins China Approval for Three-Component DTcP Combination Vaccine(4/13/2026) (Premium)
  • Oculgen Launches Global Phase II/III Trial of OCUL101 in Wet AMD(4/13/2026) (Premium)
  • Innovent Presents Preclinical Oral Data for Tri-Specific Autoimmune T-Cell Engager IBI3055(4/13/2026) (Premium)
  • BioNTech and DualityBio Report Positive Registrational Phase 2 Results for HER2 ADC in Advanced Endometrial Cancer at SG...(4/13/2026) (Premium)
  • Shanghai Minwei's Triple Agonist MWN109 Shows Strong Early Weight-Loss Data in Injectable and Oral Phase 1 Trials(4/15/2026) (Premium)
  • Sirtex's DOORwaY90 Trial Sets New Benchmark in Unresectable HCC With 100% Local Tumor Control(4/15/2026) (Premium)
  • ArkBio Advances Global Influenza Ambitions as AK0406 Begins First-in-Human Study in Australia(4/16/2026) (Premium)
  • China Drug Regulatory Weekly: Breakthrough Oncology Approvals and Novel Cell & Gene INDs Highlight April 6–12(4/16/2026) (Premium)
  • Laekna's Phase 3 AKT Inhibitor Trial Delivers Strong PFS Win in Biomarker-Selected Breast Cancer(4/16/2026) (Premium)
  • Bayer Secures China Approval for Hyrnuo (Sevabertinib) in HER2-Mutant Lung Cancer(4/16/2026) (Premium)
  • CSPC Pharma's Tissue Factor ADC SYS6051 Cleared for Clinical Trials in China(4/16/2026) (Premium)
  • Home | Contact Us | Subscribe
  • © Wicon International Group